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Abstract
Background: Many studies have shown the antinociceptive effects of cannabinoid (CB) agonists in different models of pain.
Herein, we have investigated their relevance in neuropathic pain induced by brachial plexus avulsion (BPA) in mice.
Methodology/Principal Findings: Mice underwent BPA or sham surgery. The mRNA levels and protein expression of CB1
and CB2 receptors were assessed by RT-PCR and immunohistochemistry, respectively. The activation of glial cells, MAP
kinases and transcription factors were evaluated by immunohistochemistry. The antinociceptive properties induced by
cannabinoid agonists were assessed on the 5
th and 30
th days after surgery. We observed a marked increase in CB1 and CB2
receptor mRNA and protein expression in the spinal cord and dorsal root ganglion, either at the 5
th or 30
th day after surgery.
BPA also induced a marked activation of p38 and JNK MAP kinases (on the 30
th day), glial cells, such as microglia and
astrocytes, and the transcription factors CREB and NF-kB (at the 5
th and 30
th days) in the spinal cord. Systemic treatment
with cannabinoid agonists reduced mechanical allodynia on both the 5
th and 30
th days after surgery, but the greatest
results were observed by using central routes of administration, especially at the 30
th day. Treatment with WIN 55,212-2
prevented the activation of both glial cells and MAP kinases, associated with an enhancement of CREB and NF-kB activation.
Conclusions/Significance: Our results indicate a relevant role for cannabinoid agonists in BPA, reinforcing their potential
therapeutic relevance for the management of chronic pain states.
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Introduction
Neuropathic pain, defined as ‘‘pain arising as a direct conse-
quence of a lesion or disease affecting the somato-sensorial system’’
[1], is currently one of the most difficult types of pain to treat in the
clinic. Persistent pain is often refractory to conventional analgesic
therapy, with most patients obtaining, at best, only partial relief of
symptoms [2]. In addition, most available pharmacological agents
have their use limited by undesired effects or by drug interactions.
Antidepressants and anticonvulsants have been demonstrated to
provide analgesia, but they are effective in less than one half of
patients [2]. Thus, the identification of novel therapeutic agents for
the treatment of neuropathic pain is a crucial matter of interest.
There is considerable evidence supporting a role for cannabinoids
in the modulation of pain, especially in neuropathic states [3,4].
Endogenous cannabinoids and their receptors have been found to be
expressed in key areas associated with pain processing, from
peripheral sensory nerve endings to the spinal cord and in supraspinal
centers [5,6], and markedly increase in these areas in models of
chronic pain [6–9]. The targets of cannabinoids are the two cloned
receptor subtypes, denoted CB1 and CB2; both aremembers of the G
protein-coupled receptor (GPCR) superfamily. CB1 receptor is
mostly expressed in the central nervous system (CNS), particularly
in the hippocampus, cortex, cerebellum, basal ganglia and spinal cord
[5]. On the other hand, CB2 is primarily expressed in immune cells
[10], but not exclusively outside the CNS [6,9,11].
Several studies have demonstrated the antinociceptive effects of
cannabinoid receptor agonists in rat and mouse experimental
models, including spontaneous, inflammatory and neuropathic pain
[4,6]. However, there is no evidence showing whether cannabinoids
might modulate the neuropathic pain induced by brachial plexus
avulsion (BPA). BPA usually occurs from high-speed motor vehicle
accidents or birth palsy, and typically affects young men [12]. The
management of BPA depends on the degree of damage and the site
of injury, and requires a combination of surgical procedures and
pharmacological approaches [12]. However, as in other neuro-
pathic pain syndromes, the current therapy is unsatisfactory and
produces critical collateral effects.
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e24034Our study evaluated the expression of cannabinoid receptors in
the central nervous system, and the involvement of different
signaling pathways implicated in nociception processing, such as
glial cells, MAP kinases and transcription factors in the spinal cord
structures of mice submitted to BPA. In addition, we analyzed the
effects of either non-selective or selective cannabinoid receptor
agonists in mechanical allodynia induced by BPA, and assessed
whether cannabinoid agonists might modulate nociceptive signal-
ing pathways to produce analgesia in this pain model.
Results
Neuropathic pain-like behavior induced by BPA
In this work, we observed the development of long-lasting
mechanical allodynia in the right hindpaw of mice submitted to
BPA observed until the 30
th day after surgery (two-way ANOVA,
F=11.24, df=8 and p,0.001 for time), when compared to the
sham-operated group, which did not develop differences in the
mechanical threshold (Figure 1). However, the animals displayed
good overall health after surgery, with standard locomotor activity
throughout the experimental period of evaluation.
Up-regulation of CB1 and CB2 receptor expression levels
in the DRG and spinal cord after BPA
As cannabinoid receptors play an important role in neuropathic
pain [4,6], we further evaluated the expression of both
cannabinoid receptors after BPA in mice. In this set of
experiments, we assessed the mRNA levels of CB1 and CB2
receptors in the DRG and spinal cord of mice submitted to BPA
(at both the 5
th and 30
th days after the surgical procedure). The
RT-PCR assay revealed constitutive expression of CB1 and CB2
receptors in both evaluated anatomical structures in naı ¨ve and
sham-operated mice. Notably, a significant increase in CB1
receptor mRNA expression was observed only on the 30
th day
after BPA in the DRG (one-way ANOVA, F=7.44, df=4,
p,0.01), and on the 5
th and the 30
th days in the dorsal horn of the
spinal cord of operated mice (one-way ANOVA, F=20.24, df=4,
p,0.01) (Figure 2A and C). Of great interest, there was an
increase in CB2 receptor mRNA levels in the DRG (one-way
ANOVA, F=6.63, df=4, p,0.01) and in the dorsal horn of the
spinal cord on the 5
th and 30
th (one-way ANOVA, F=13.77,
df=4, p,0.05 and p,0.01) days after BPA (Figure 2B and D).
These results were confirmed by immunohistochemical analysis of
CB1 and CB2 receptor positivity in sections from the DRG and
dorsal horn of the spinal cord of operated mice. Notably, our
results also revealed a significant increase in the expression of both
receptors CB1 and CB2 in regions of the DRG (one-way ANOVA,
F=12.57, df=4, p,0.05 and F=7.28, df=4, p,0.01) (Figure 3A
and D) and dorsal horn of the spinal cord associated mainly with
the termination of nociceptive primary afferents (one-way
ANOVA, F=21.60, df=4, p,0.05 and F=6.18, df=4,
p,0.01) (Figure 3B and E), according to assessment on 5
th and
30
th days after surgery. In addition, there was an increase in the
expression of both CB1 and CB2 receptors in the somatosensory
cortex, especially in the cingulate cortex, of mice assessed 30 days
after BPA (one-way ANOVA, F=38.31, df=4, p,0.05 and
F=24.38, df=4, p,0.05) (Figure 3C and F, and Figure S1).
Therefore, it is tempting to suggest that both CB1 and CB2
receptors are up-regulated after BPA in mice in several structures
related to pain transmission and/or modulation, including the
DRG, dorsal horn of the spinal cord and cingulate cortex.
Increase in activation of glial cells, MAP kinases and the
transcriptional factors CREB and NF-kB in the spinal cord
after BPA
Under normal conditions, glial cells are known for having a
number of housekeeping functions in the central nervous system
[13]. However, glial cells can contribute to neuropathic pain
processing by the activation of intracellular pathways, such as the
MAP kinase family and related transcription factors, which leads
to an increase in inflammatory mediators and up-regulation of
specific receptors [13]. According to these data, we further
investigated some possible central mechanisms that could be
involved in neuropathy induced by the BPA procedure. Figure 4
(A and B) shows that immunoreactivity for microglia (Iba-1) and
astrocytes (GFAP) was increased on the 5
th and 30
th days after
surgery (one-way ANOVA, F=17.35, df=4, p,0.01 and
F=15.08, df=4, p,0.01) (Figure S2). Furthermore, phosphory-
lated p38 and JNK MAP kinases were markedly increased in the
dorsal horn of the spinal cord, but only on the 30
th day after BPA
(one-way ANOVA, F=41.43, df=4, p,0.01 and F=24.77,
df=4, p,0.01), with no alterations in expression on the 5
th day
(Figure 4C and D and Figure S2). Likewise, the transcription
factor CREB was augmented on the 30
th day after BPA (one-way
ANOVA, F=6.83, df=4, p,0.01) (Figure 4E and Figure S2), and
the transcription factor NF-kB (p65) was increased on both the 5
th
or 30
th (one-way ANOVA, F=13.02, df=4, p,0.05) days
following surgery in the dorsal horn of the spinal cord (Figure 4F
and Figure S2). The sham-operated mice did not display any
significant alteration in immunoreactivity in comparison to the
naı ¨ve group. Altogether, these data clearly demonstrate the
importance of glial cells, protein kinases and different transcription
factors in the modulation of BPA-induced neuropathic behavior.
Systemic treatment with cannabinoid agonists inhibited
neuropathic pain-like behavior induced by BPA
An increasing body of evidence has emerged indicating that
cannabinoids and their receptors are up-regulated in the CNS,
and appear to be involved in neuropathic pain [6,9]. Taking this
into account, we next evaluated the effects of cannabinoid agonists
Figure 1. Mechanical allodynia induced by brachial plexus
avulsion (BPA) in mice. Response of frequency of the right hindpaw
assessed at several time-points by von Frey hair 0.4 g in sham-operated
and operated (BPA) mice. Data are expressed as mean 6 SEM (n=4–6/
group).
##p,0.01, significantly different from the sham-operated
group (two-way ANOVA with Bonferroni’s post hoc test). B, Baseline
withdrawal threshold before surgery.
doi:10.1371/journal.pone.0024034.g001
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separate groups of animals were treated with the non-selective
cannabinoid agonist WIN 55,212-2, the selective CB1 receptor
agonist ACEA, or the selective CB2 receptor agonist JWH-015, all
given by different routes of administration, on the 5
th or 30
th day
after BPA. As shown in Figure 5 (A and D), mechanical allodynia
was significantly reduced for 6 h after systemic administration of
WIN 55,212-2 (3 mg/kg, i.p.), when given on the 5
th day post-
surgery, with inhibition of 3966%, based on the area under the
curve (AUC) (two-way ANOVA, F=62.32, df=6 and p,0.001
for time, and F=88.91, df=3 and p,0.001 for treatment). In
addition, WIN 55,212-2 administered on the 30
th day, either at
doses of 3 or 5 mg/kg (i.p.) produced long-lasting inhibition (for
8 h after treatment) (two-way ANOVA, F=46.36, df=6 and
p,0.01 for time, and F=68.36, df=3 and p,0.001 for
treatment), with inhibition of 38610% and 6065%, respectively.
On the other hand, i.p. treatment with ACEA (10 mg/kg), a
CB1 selective agonist, significantly reduced mechanical allodynia
only when assessed 1 h after treatment, when administered on the
5
th day post-surgery (two-way ANOVA, F=46.42, df=6 and
p,0.001 for time, and F=37.39, df=3 and p,0.001 for
treatment); nonetheless, this did not produce a significant
inhibition based on the AUC (Figure 5B). Conversely, on the
30
th day, both doses of ACEA significantly reduced mechanical
allodynia 1 h after treatment (two-way ANOVA, F=53.33, df=6
and p,0.001 for time, and F=73.92, df=3 and p,0.001 for
treatment), but with a slight effect according to the AUC
(Figure 5E). In addition, on the 5
th day after BPA, the selective
CB2 receptor agonist JWH-015 (1 and 10 mg/kg), given by the i.p.
route, was able to significantly reduce mechanical allodynia (two-
way ANOVA, F=28.83, df=6 and p,0.001 for time, and
F=44.12, df=3 and p,0.001 for treatment) (Figure 5C). On the
other hand, JWH-015 (1 and 10 mg/kg, i.p.) slightly reduced
BPA-induced allodynia within the first two hours of administra-
tion, and did not produce any significant effect when dosed 30
days after surgery (two-way ANOVA, F=28.41, df=6 and
p,0.001 for time, and F=75.91, df=3 and p,0.001 for
treatment, Figure 5F). It is important to mention that under these
treatment protocols, none of the cannabinoid treatments produced
any significant motor deficit, no typical signs of catalepsy or
hypothermia, and failed to change the basal threshold of pain,
according to the tetrad test used to evaluate cannabinoid-related
central effects (Supplementary Methods and Table S1).
Local treatment with cannabinoid agonists failed to
inhibit neuropathic pain-like behavior induced by BPA
In order to assess the involvement of local activation of the
cannabinoid system following BPA-induced mechanical hypersen-
sitivity, separate groups of mice received peripheral injection of the
non-selective (WIN 55,212-2), the CB1 selective (ACEA) or the
CB2 selective (JWH-015) cannabinoid agonists by the i.pl. route.
However, the agonists WIN 55,212-2 (10 and 30 mg/paw) and
Figure 2. Evaluation of CB1 receptor (CB1) and CB2 receptor (CB2) mRNA levels in CNS structures of mice submitted to brachial
plexus avulsion (BPA). The mRNA levels of the CB1 and CB2 receptors were evaluated in the dorsal root ganglia (DRG) (A and B) and dorsal horn of
the spinal cord (C and D), respectively. GAPDH mRNA was used to normalize the relative amount of mRNA. N (naı ¨ve mice), Sh 5 d (sham-operated
group 5 days after BPA), Op 5 d (operated group 5 days after BPA), Sh 30 d (sham-operated group 30 days after BPA) and Op 30 d (operated group
30 days after BPA). Data are expressed as mean 6 SEM (n=3/group), and are representative of three independent experiments. *p,0.05 and
**p,0.01, significantly different from the respective sham-operated group (one-way ANOVA with Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0024034.g002
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th or
30
th day after surgery, did not produce significant changes in
mechanical allodynia induced by BPA in mice (Figure S3). On the
other hand, when the CB1 selective agonist ACEA (30 mg/paw)
was administered on the 5
th day after surgery, it significantly
reduced mechanical allodynia until 2 h after treatment (two-way
ANOVA, F=57.96, df=d and p,0.001 for time, and F=74.88,
df=3 and p,0.001 for treatment); however, this did not result in
significant inhibition when calculated based on the AUC.
Contrarily, on the 30
th day after surgery, ACEA treatment did
not reduce mechanical allodynia induced by BPA.
Neuropathic pain-like behavior induced by BPA was
greatly inhibited by central treatment with cannabinoid
agonists
Next, to verify the possible involvement of spinal pathways in
the modulating actions of cannabinoids following BPA, animals
were treated with the cannabinoid agonists by the i.t route. As
depicted in Figure 6A and C, i.t. treatment with WIN 55,212-2
(1 mg/site) and JWH-015 (1 mg/site) significantly reduced me-
chanical allodynia induced by BPA for 4 h (two-way ANOVA,
F=45.33, df=6 and p,0.001 for time, and F=37.57, df=3 and
p,0.001 for treatment) or 6 h (two-way ANOVA, F=22.11,
df=6 and p,0.001 for time, and F=19,84, df=3 and p,0.001
for treatment) after treatment, respectively. On the other hand, i.t.
treatment with ACEA (10 mg/site), given 5 days after surgery,
showed a slight reduction in mechanical allodynia caused by BPA
(Figure 6B) (two-way ANOVA, F=43.95, df=6 and p,0.001 for
time, and F=31.82, df=3 and p,0.001 for treatment). When
evaluated on the 30
th day after BPA, the administration of WIN
55,212-2 (1 mg/site) significantly reduced mechanical allodynia
until 4 h after treatment (two-way ANOVA, F=52.35, df=6 and
p,0.001 for time, and F=44.05, df=3 and p,0.001 for
treatment) (Figure 6D). Likewise, treatment with ACEA (30 mg/
site) almost abolished mechanical allodynia for 2 h after treatment
(Figure 6E) (two-way ANOVA, F=46.91, df=6 and p,0.001 for
time, and F=16.64, df=2 and p,0.001 for treatment). Similarly,
the treatment with JWH-015 (1 and 10 mg/site) on the 30
th day
after BPA produced a marked and significant reduction in
mechanical nociceptive responses for 4 h after treatment (two-
way ANOVA, F=24.53, df=6 and p,0.001 for time, and
F=79.83, df=3 and p,0.001 for treatment), with inhibition of
4469% and 3067%, respectively (Figure 6F).
In another set of experiments, the cannabinoid agonists were
administered by the i.c.v. route to verify the possible supraspinal
role of cannabinoids in the neuropathic pain-like behavior
associated with BPA. As shown in Figure 7 (A and C), i.c.v.
treatment with WIN 55,212-2 (1 and 5 mg/site) and JWH-015
(10 mg/site) on the 5
th day following surgery slightly, but
significantly, reduced allodynia induced by BPA for 1 h (two-
way ANOVA, F=37.28, df=6 and p,0.001 for time, and
F=27.37, df=3 and p,0.001 for treatment) and 4 h (two-way
ANOVA, F=40.83, df=6 and p,0.001 for time, and F=38.29,
df=3 and p,0.001 for treatment) after treatment, respectively.
Surprisingly, treatment with ACEA (10 and 30 mg/site) did not
reduce the nociceptive response when administered on the 5
th day
after surgery. However, i.c.v. administration of WIN 55,212-2
(Figure 7D), ACEA (Figure 7E) and JWH-015 (Figure 7F) 30 days
after the surgical procedure markedly reduced mechanical
allodynia induced by BPA for up to 8 h (two-way ANOVA,
F=23.84, df=6 and p,0.001 for time, and F=30.28, df=3 and
p,0.001 for treatment), 6 h (two-way ANOVA, F=24.99, df=6
and p,0.001 for time, and F=50.67, df=3 and p,0.001 for
treatment) and 2 h (two-way ANOVA, F=25.09, df=6 and
Figure 3. The CB1 receptor (CB1) and CB2 receptor (CB2) immunoreactivity in the dorsal root ganglion (DRG), the dorsal horn of the
spinal cord and the cingulate cortex after brachial plexus avulsion (BPA) in mice. CB1 and CB2 receptor expression was evaluated in the
DRG (A and D), the dorsal horn of the spinal cord (B and E) and the cingulate cortex (C and F) in N (naı ¨ve mice), Sh 5 d (sham-operated group 5 days
after BPA), Op 5 d (operated group 5 days after BPA), Sh 30 d (sham-operated group 30 days after BPA) and Op 30 d (operated group 30 days after
BPA). Immunostaining intensity and area were quantified by image analysis and are expressed as arbitrary units (mean 6 SEM, n=4/slices of 4–6/
group).*p,0.05 and **p,0.01, significantly different from the respective sham-operated group (one-way ANOVA with Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0024034.g003
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treatment) after treatment with the highest dose, respectively.
This collection of data clearly demonstrates that both CB1 and
CB2 receptors might be distinctly up-regulated in different areas of
the CNS in a time-dependent manner.
Taken together, this series of experimental evidence suggests
that on the 5
th day, either peripheral or spinal cannabinoid
receptors seem to be related to the onset and maintenance of
mechanical allodynia induced by BPA. On the other hand, on the
30
th day, i.t. and i.c.v. treatment with the cannabinoid agonists
showed greater inhibition of mechanical allodynia induced by
BPA which suggests, at least in part, the principal action of spinal
and supra-spinal cannabinoid receptors in the persistence of
allodynia induced by BPA.
Effect of cannabinoid antagonists in the analgesic
response induced by WIN 55,212-2 in mice
To confirm if the analgesic effects of cannabinoid agonists are
due to specific receptor activation, we included a group of
experiments using the selective CB1 (AM 251, 3 mg/kg, i.p.) or
Figure 4. Brachial plexus avulsion (BPA)-induced mechanical hypersensitivity on the expression of glial cells, MAP kinases and
transcription factors in the dorsal horn of the spinal cord in mice. Immunostaining of activated microglia (Iba-1, A), astrocytes (GFAP, B),
phospho-p38 (p-p38, C) and phospho-JNK (p-JNK, D) MAP kinases, phospho-CREB (p-CREB, E) and phospho-p65 NF-kB (p-p65, F) transcription factors
in N (naı ¨ve mice), Sh 5 d (sham-operated group 5 days after BPA), Op 5 d (operated group 5 days after BPA), Sh 30 d (sham-operated group 30 days
after BPA) and Op 30 d (operated group 30 days after BPA). Immunostaining intensity and area were quantified by image analysis and are expressed
as arbitrary units (mean 6 SEM, n=4/slices of 4–6/groups). *p,0.05 and **p,0.01, compared with sham-operated of the respective group and time
(one-way ANOVA followed by Bonferroni’s post hoc test). JNK: c-Jun N-terminal kinase; CREB: cAMP response element-binding protein; p65 NF-kB:
nuclear phospho-p65 nuclear factor-kB (NF-kB).
doi:10.1371/journal.pone.0024034.g004
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(3 mg/kg, i.p.) administration. The results depicted in Figure 8B
demonstrate a minor reversion of WIN 55,212-2-induced
analgesia in the CB2-selective antagonist-treated group on the
5
th day after BPA (two-way ANOVA, F=27.82, df=6 and
p,0.001 for time, and F=43.86, df=3 and p,0.001 for
treatment). On the other hand, the treatment with the CB1-
selective antagonist did not prevent the reduction of mechanical
allodynia produced by WIN 55,212-2 treatment at this experi-
mental time-point (Figure 8A). Moreover, when different groups of
mice were treated with the CB1-selective antagonists (two-way
ANOVA, F=43.53, df=6 and p,0.001 for time, and F=87.32,
df=3 and p,0.001 for treatment) or CB2-selective antagonists
(two-way ANOVA, F=34.96, df=6 and p,0.001 for time, and
F=182.3, df=3 and p,0.001 for treatment) on the 30
th day after
surgery, both drugs were able to markedly reverse the inhibition
produced by WIN 55,212-2 (3 mg/kg, i.p.) treatment for 2 h after
antagonist treatment (Figure 8C e D).
Effect of cannabinoid agonist treatment on knockdown
of CB1 and CB2 in mice
Next, to verify the possible involvement of spinal cannabinoid
receptors in the modulation of mechanical allodynia induced by
BPA,weperformed intrathecalpre-treatment withselectiveCB1 and
CB2 antisenseoligodeoxynucleotides(AS-ODN) usedtoknockdown
theexpressionofthesereceptorsinthelumbarspinalcordafterBPA.
The group of mice that received the mismatch control ODN (MM
AS-ODN) did not demonstrate interference in the pain threshold,
and the treatment with the cannabinoid agonist WIN 55,212-2
(3 mg/kg, i.p.) produced a significant reduction in mechanical
allodynia induced by BPA (two-way ANOVA, F=41.49 df=6 and
p,0.001 for time, and F=52.50, df=1 and p,0.001 for treatment)
when assessed on the 5
th or 30
th day after surgery (Figure 9A–D).
Figure 9A shows that treatment of mice with the CB1 AS-ODN
(12.5 mg/site, 26day, i.t.) delayed by 1 h the inhibition produced by
WIN 55,212-2 (3 mg/kg, i.p.) pre-treatment (two-way ANOVA,
F=65.25, df=6 and p,0.001 for time, and F=26.40, df=2 and
p,0.001 for treatment), when administered for three consecutive
days and evaluated on the 5
th day after BPA. However, when the
animals were treated for three consecutive daysand evaluated on the
30
th day after BPA, the CB1 AS-ODN almost completely prevented
(for 6 h after treatment) the analgesia produced by WIN 55,212-2
(3 mg/kg, i.p.), with an inhibition of 90620% (two-way ANOVA,
F=49.08, df=6 and p,0.001 for time, and F=16.35, df=2 and
p,0.001 for treatment) (Figure 9C). A similar result was observed
when micereceived the CB2 AS-ODN (12.5 mg/site, 26day, i.t.) for
three consecutive days and were evaluated on the 5
th and 30
th days
after BPA, showing an inhibition in WIN 55,212-2-induced
Figure 5. Systemic administration of cannabinoid agonists inhibits mechanical allodynia induced by brachial plexus avulsion (BPA)
in mice. Response frequency of the right hindpaw assessed at several time-points in sham-operated and operated (BPA) mice treated with the non-
selective CB1 and CB2 agonist, WIN 55,212-2 (3–5 mg/kg, i.p.), the selective CB1 agonist, ACEA (1–10 mg/kg, i.p.), the selective CB2 agonist, JWH-015
(1–10 mg/kg, i.p.) or vehicle (10 ml/kg, i.p.), administered on the 5
th (A, B and C) or 30
th (D, E and F) day after surgery. Data are expressed as mean 6
SEM (n=4–6/group). *p,0.05 and **p,0.01, significantly different from the operated group treated with vehicle (two-way ANOVA with Bonferroni’s
post hoc test). B, Baseline withdrawal threshold before surgery. 0, baseline withdrawal threshold after surgery on the day of the experiment (5
th and
30
th days).
doi:10.1371/journal.pone.0024034.g005
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ANOVA, F=50.77, df=6 and p,0.001 for time, and F=30.01,
df=2 andp,0.001 for treatment)and 91615%(two-wayANOVA,
F=56.48, df=6 and p,0.001 for time, and F=29.68, df=2 and
p,0.001 for treatment), respectively (Figure 9B and D).
Extending the functional evidence, treatment with the AS-ODN
was able to diminish the expression of both CB1 and CB2 receptors
in the mouse spinal cord, when compared with the group treated
with MM AS-ODN, evaluated by immunohistochemical analysis
(Figure S4). These results suggest a major participation of the CB2
receptor on the 5
th day after surgery, when a large inflammatory
response is involved and crosstalkof both CB1 and CB2 receptors on
the 30
th day after surgery, when central sensitization is involved.
Effects of cannabinoid agonists on the activation of glial
cells, MAP kinases, and transcription factors in the spinal
cord after BPA
In order to further evaluate the possible mechanisms involved in
the analgesic actions of cannabinoid agonists, we next assessed
whether treatment with WIN 55,212-2 was able to decrease the
activation and/or expression of glial cells, as well as the activation
MAP kinases and transcription factors in the spinal cord of mice
on the 5
th or 30
th day after BPA. Of high interest, acute (single
administration) or prolonged treatment (five administrations in a
12/12 h schedule of treatment) with the non-selective cannabinoid
agonist WIN 55,212-2 (3 mg/kg, i.p.) markedly reduced the
increased activation of microglia (6069% and 6865%, respec-
tively) (one-way ANOVA, F=19.96, df=5, p,0.001, Figure 10A),
astrocytes (8467% and 9761%, respectively) (one-way ANOVA,
F=7.16, df=5, p,0.001, Figure 10B), phospho-p38 (67611%
and 9262%, respectively) (one-way ANOVA, F=19.14, df=5,
p,0.001, Figure 10C) and phospho-JNK (8664% and 8263%,
respectively) (one-way ANOVA, F=24.04, df=5, p,0,001,
Figure 10D), only on the 30
th day (Figure S5) after surgery. On
the other hand, there were an increase in the activation of
phospho-p38 and CREB following the pre-treatment of animals
with WIN 55,212-2 (3 mg/kg, i.p.) on the 5
th day after surgery
(Figure 10E) and an increase in the p65 subunit of NF-kB 30 days
after BPA (Figure 10F and Figure S5) (ANOVA, p,0.05). Taken
together, this series of experimental evidence suggests that the
analgesic effects of cannabinoid agonists on neuropathic hyper-
sensitivity depend, at least in part, on the ability of these
compounds to inhibit glial cells, mainly microglia and astrocytes
via the down-regulation of MAP kinase activation.
Discussion
In this study, we demonstrate for the first time that mechanical
allodynia induced by BPA in mice is regulated by either systemic
or central treatment with both CB1 and CB2 cannabinoid agonists.
Figure 6. Effects of spinal (i.t.) administration of cannabinoid agonists on mechanical allodynia induced by brachial plexus avulsion
(BPA) in mice. Response frequency of the right hindpaw assessed at several time-points in operated (BPA) mice treated with the non-selective CB1
and CB2 agonist, WIN 55,212-2 (1–5 mg/site, i.t.), the selective CB1 agonist ACEA (10–30 mg/site, i.t.), the selective CB2 agonist, JWH-015 (1–10 mg/site,
i.t.) or vehicle (5 ml/site, i.t.), administered on the 5
th (A, B and C) or 30
th (D, E and F) day after surgery. Data are expressed as mean 6 SEM (n=4–6/
group). *p,0.05 and **p,0.01, significantly different from the operated group treated with vehicle (two-way ANOVA with Bonferroni’s post hoc test).
B, Baseline withdrawal threshold before surgery. 0, baseline withdrawal threshold after surgery on the day of the experiment (5
th and 30
th days).
doi:10.1371/journal.pone.0024034.g006
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regulation of both CB1 and CB2 receptors in the DRG, the spinal
cord and the somatosensory cortex (cingulate cortex) after BPA.
Our data also show that the mechanisms responsible for
cannabinoid agonist-mediated analgesic actions are primarily
associated with the ability of these compounds to prevent the
activation of microglia and astrocytes cells, and to inhibit the
phosphorylation of MAP kinases, such as p38 and JNK, associated
with an increase in the expression of the transcription factors
CREB and NF-kB. Additionally, our results also support a major
involvement of CB2 receptors in the acute phase (5
th day) and both
CB1 and CB2 receptors in the chronic phase (30
th day) of
neuropathic pain induced by BPA.
In models of chronic pain, several studies have suggested the up-
regulation of both cannabinoid receptors in different areas of the
central nervous system [6–9]. The results of the present study
demonstrate that there is a basal mRNA expression level of both
CB1 and CB2 receptors in the DRG and spinal cord of naı ¨ve mice,
and also demonstrate up-regulation of both receptors on the 5
th
and 30
th days after BPA surgery in mice. However, we are not
currently able to define in what cell type the up-regulation of
cannabinoid receptors takes place, and further studies are
necessary to clarify this point. Previous studies have demonstrated
an increase in CB2 receptor expression in non-neuronal cells [10]
and in central neurons after nerve injury [6,11]. In the same way,
the expression of CB1 receptors has been observed in neuronal
cells and in a smaller proportion of non-neuronal cells, chiefly after
nerve injury [5,11]. Moreover, earlier studies have demonstrated
that in models of chronic pain, there is an increase in the
production of endocannabinoids in central areas, especially in the
spinal cord [11]. Therefore, we might suggest that increased
expression of cannabinoid receptors is one of the pathways
activated to control BPA-related neuropathic pain.
The increase in cannabinoid receptor expression observed after
BPA surgery was aligned with the augmented activation of
microglia and astrocytes in the spinal cord of mice, on both the
5
th and 30
th days after BPA. It has been reported that activation of
glial cells in the central nervous system contributes to aberrant pain
behavior and plays an important role in central sensitization of
central neurons [13]. Although we are not able to demonstrate the
localization of cannabinoid receptor expressionin the present study,
many studies have demonstrated that increased CB2 receptor
expression after nerve injury is chiefly related to microglial
activation [10], while CB1 receptors have been found in many
types of cells, including microglia, astrocytes and neurons in the
spinal cord of rodents [5,11,14]. The involvement of glia in
neuropathic pain has been confirmed by treatment with minocy-
cline, an inhibitor of activatedmicroglia, which significantly reduces
Figure 7. Effects of supraspinal (i.c.v.) treatment with cannabinoid agonists on mechanical allodynia induced by brachial plexus
avulsion (BPA). Response frequency of the right hindpaw assessed at several time-points in operated (BPA) mice treated with the non-selective CB1
and CB2 agonist, WIN 55,212-2 (1–5 mg/site, i.c.v.), the selective CB1 agonist, ACEA (10–30 mg/site, i.c.v.), the selective CB2 agonist, JWH-015 (1–10 mg/
site, i.c.v.) or vehicle (2 ml/site, i.c.v.), administered on the 5
th (A, B and C) or 30
th (D, E and F) day after surgery. Data are expressed as mean 6 SEM
(n=4–6/group). *p,0.05 and **p,0.01, significantly different from the operated group treated with vehicle (two-way ANOVA with Bonferroni’s post
hoc test). B, Baseline withdrawal threshold before surgery. 0, baseline withdrawal threshold after surgery on the day of the experiment (5
th and 30
th
days).
doi:10.1371/journal.pone.0024034.g007
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neuropathy in rodents [15]. In this work, we demonstrated that
acute and prolonged treatment with WIN 55,212-2 reduced the
activation of both microglia and astrocytes on the 30
th day after
surgery, suggesting that cannabinoid agonists are involved in glial
cell regulation.
Recent research on central sensitization following nerve injury
has indicated a relevant role for the MAP kinases JNK and p38 in
nociceptive hyper-reactivity [16,17]. In fact, JNK and p38
activation was found to be increased in animal models of acute
and persistent pain [16,17]. Some studies have suggested that
inhibition of p38 prevents mechanical allodynia and the develop-
ment of neuropathic pain in rodents [16], and that JNK inhibitors
can reverse mechanical allodynia induced in neuropathic models
[17]. The mechanical allodynia observed inthe BPA model was also
preceded by a marked activation of both MAP kinases in the spinal
cord of mice, according to the assessment performed 30 days after
surgery. Additionally, both acute and long-term treatment with
WIN 55,212-2 reduced the activation of JNK and p38 MAPKs
when observed on the 30
th day after surgery. These results suggest
that MAP kinases such as JNK and p38 play a pivotal role in the
control of neuronal hyperexcitability and neuropathic pain after
BPA,whencentralsensitizationisinvolved.However,onthe5
thday
after surgery, an increase in p38 phosphorylation occurred after
acute and long-term treatment with WIN 55,212-2. It is known that
both cannabinoid receptors are able to phosphorylate and activate
different MAPK members, inducing the transcription of genes with
different effects on cell survival [18]. So, the increase in p38
Figure 8. Effects of pre-treatment with selective cannabinoid antagonists, administered on the 5
th and 30
th days after brachial
plexus avulsion (BPA), on analgesia produced by WIN 55,212-2 treatment in mice. Response frequency of the right hindpaw assessed at
several time-points in operated (BPA) mice treated with vehicle (10 ml/kg, i.p.) or a CB1-selective antagonist (AM 251, 3 mg/kg, i.p.) (A and C) or a CB2-
selective antagonist (AM 630, 1 mg/kg, i.p.) (B and D) 30 min before systemic treatment with the non-selective agonist, WIN 55,212-2 (3 mg/kg, i.p.)
administered on the 5
th (A and B) or 30
th (C and D) day after surgery. Data are expressed as mean 6 SEM (n=4–6/group).
#p,0.01, significantly
different from the operate-vehicle-treated group. **p,0.01, significantly different from the WIN 55,212-2 treated group, and
‘p,0,01 is significantly
different from sham-operated treated with vehicle (two-way ANOVA with Bonferroni’s post hoc test).
doi:10.1371/journal.pone.0024034.g008
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the processes of neuropathic pain induction in the spinal cord.
However, further studiesarenecessaryto investigate this hypothesis.
In neuropathic pain, numerous pro-inflammatory cytokines or
neurotransmitters are produced and released in the spinal cord
after injury, and in turn lead to increased CREB and NF-kB
phosphorylation in superficial dorsal horn neurons, contributing
to neuropathic pain [19,20]. In the BPA model, there was a
great increase in CREB phosphorylation in the spinal cord on
the 30
th day after surgery. In addition, an increase in NF-kB
activation was observed in the spinal cord of mice on both the
5
th and 30
th days after BPA. This set of results suggests that the
BPA model produces alterations in the spinal cord that involve
glial cell activation and an increase in MAP kinases activation
through the activation of transcription factors, such as CREB
and NF-kB, that could contribute to the genesis and mainte-
nance of pain after nerve injury. Intriguingly, the activation of
the transcription factors CREB and p65 NF-kBo b s e r v e di nt h e
spinal cord after BPA was significantly increased by acute or
prolonged treatment with WIN 55,212-2 on the 5
th and the 30
th
days after BPA, respectively. Despite their participation in some
pathological states like neuropathic pain, both transcription
factors regulate additional cellular responses, including prolifer-
ation, survival and differentiation [20,21]. So, the increase in
CREB and p65 NF-kB activation by WIN 55,212-2 treatment
could induce a protective effect that needs to be investigated
further. There are published data showing that cannabinoid
agonists are able to increase CREB phosphorylation, an effect
that seems to be important for regulating the growth of neurites
in cultured neuronal cells [22,23]. In addition, another study has
Figure 9. Effect of treatment with antisense oligodeoxinucleotide (AS-ODN) against the CB1 or CB2 receptor on mechanical
allodynia induced by brachial plexus avulsion (BPA) in mice. Different groups of operated (Op) mice received an i.t. injection twice daily of
mismatch AS-ODN (12.5 mg/site), CB1 AS-ODN (12.5 mg/site) or CB2 AS-ODN (12.5 mg/site). Systemic administration of WIN 55,212-2 (3 mg/kg, i.p.)
produced a significant reduction of mechanical allodynia induced by BPA on the 5
th (A and B) and 30
th (C and D) days after surgery. The
antinociceptive activity of WIN 55,212-2 (3 mg/kg, i.p.) was inhibited by both CB1 AS-ODN (12.5 mg/site, i.t.) and CB2 AS-ODN (12.5 mg/site, i.t.) on the
5
th (A and C) and 30
th (B and D) days after surgery, respectively. AS-ODN were administered on three consecutive days starting on the 2
nd and 27
th
days after BPA surgery. The mice which received mismatch (MM) AS-ODN demonstrated similar responses throughout the testing period. Data are
expressed as mean 6 SEM (n=4–6/group). *p,0.05 and **p,0.01, significantly different from the operated group that received MM AS-ODN and
treated with WIN 55,212-2 (two-way ANOVA with Bonferroni’s post hoc test).
#p,0.01, significantly different from operated-mice group (Op) that
received MM AS-ODN and treated with vehicle. B, Baseline withdrawal threshold before surgery. 0, baseline withdrawal threshold after surgery on the
day of the experiment (5
th and 30
th days).
doi:10.1371/journal.pone.0024034.g009
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activation in neurons is involved in neuronal survival and
neuritic growth depending on the degree and site of activation,
whereas activation in glial cells promotes the release of
inflammatory mediators, and thereby contributes to the
inflammatory process [24]. Taken together, the activation of
CREB and p65 NF-kB may have a beneficial effect in terms of
the cannabinoid effect on neuropathic pain induced by BPA.
Several studies have demonstrated that cannabinoids might act
as analgesics [3,4], and it has been demonstrated that the
antinociceptive effects of cannabinoids are predominantly medi-
ated through CB1 receptors [8,25]. However, many studies have
pointed out CB2 receptor agonists as new therapeutic options to
treat chronic pain without the psychotropic effects produced by
CB1 receptor agonists [9,26]. Our results revealed the participa-
tion of CB2 receptors in the initial phase of neuropathic pain
Figure 10. Effect of cannabinoid agonist on the expression of glial cells, MAP kinases and transcription factors in the dorsal horn of
the spinal cord after brachial plexus avulsion (BPA) in mice. Effects of acute (once) or long-term (five times, 12612 h) treatment with WIN
55,212-2 (3 mg/kg, i.p.) on the 5
th or 30
th days after BPA on the expression of activated microglia (Iba-1, A), astrocytes (GFAP, B), phospho-p38 (p-p38,
C), phospho-JNK (p-JNK, D), phospho-CREB (p-CREB, E) and phospho-p65 NF-kB (p-p65, F). Immunostaining intensity and area were quantified by
image analysis and are expressed as arbitrary units (mean 6 SEM, n=4/slices of 4–6/groups). *p,0.05 and **p,0.01, compared with sham-operated
of respective group and time (one-way ANOVA followed by Bonferroni’s post hoc test). JNK: c-Jun N-terminal kinase; CREB: cAMP response element-
binding protein; p65 NF-kB: nuclear phospho-p65 nuclear factor-kB (NF-kB).
doi:10.1371/journal.pone.0024034.g010
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receptors in the late phase of neuropathy. The participation of
CB2 receptors in initial phase of neuropathic pain in the BPA
model could be related to its known anti-inflammatory activity,
probably acting in immune cells in the periphery and in glial cells
in the spinal cord. Recent studies have reported that CB2 receptor
stimulation reduces microglial activation and the release of
inflammatory mediators such as cytokines and chemokines
[9,27]. However, further studies are required to confirm the cell
type related to the CB2 receptor-mediated effects in the BPA
model.
Our data also suggest that CB1 receptors can participate in pain
control, chiefly in the late phase of neuropathic pain (30 days after
BPA), probably by activating receptors located at the spinal and
supra-spinal levels. This proportion is based on the fact that both
systemic and intraplantar administration of the CB1 selective
agonist displayed only a moderate effect on mechanical allodynia
induced by BPA, when compared to the i.t. or i.c.v. routes. The
significant inhibition of neuropathic pain by cannabinoid agonists
when dosed via central routes could be related to increased
cannabinoid receptor expression in the areas of the CNS involved
in pain control [7,8]. To explore the relevance of cannabinoid
receptors in the central regulation of mechanical allodynia induced
by BPA, we used the distinct approaches of blocking or knocking
down CB1 and CB2 receptors in the spinal pathway. The results
obtained by employing AS-ODN technology or the use of selective
cannabinoid receptor antagonists confirmed the results obtained
by the treatment of mice with cannabinoid selective agonists,
supporting the major participation of CB2 receptors in the early
phase, and both CB1 or CB2 receptors in the late phase after BPA
surgery. The attenuation of the antinociceptive action of WIN
55,212-2 after antisense oligonucleotide or antagonist administra-
tion was reflected by the reduction in both CB1 and CB2 receptors
in the spinal cord. Others studies have confirmed the modulation
of nociceptive thresholds by cannabinoid receptors by treatment
with selective antisense and antagonists, or by using CB1
2/2 or
CB2
2/2 knockout mice [28,29]. These studies, as well as a
number of further investigations, have demonstrated the potential
of antisense strategies in pain research [for reviews, see 30,31]. In
general, antisense oligonucleotides use Watson–Crick base
pairing to specifically hybridize to mRNA sequences comple-
mentary to those contained in the antisense molecule. For this
hybridization to occur, the targeted mRNA sequence must be
accessible to the oligonucleotide, and several other events must
occur [32]. The mechanism by which oligonucleotides enter cells
remains controversial, but probably involves fluid phase pinocy-
tosis, receptor-mediated endocytosis, or both. Oligonucleotides
must arrive at the mRNA intact, avoiding destruction in
lysosomes and degradation by the various endo- and exonucleases
present intracellularly and within serum and tissues [33]. Finally,
the oligonucleotides must hybridize to target mRNAs with
sufficient affinity and specificity, and evoke a mechanism of
action leading to mRNA inactivation or destruction. Antisense
oligonucleotides inhibit protein expression, in most cases, through
RNase-H-mediated cleavage of target mRNA. RNase H is an
endonuclease that recognizes RNA–DNA duplexes and selec-
tively cleaves the RNA strand [34,35]. The mechanism is
catalytic: once an RNA molecule is cleaved, the antisense
oligonucleotide is thought to dissociate from the duplex and
become available to bind a second target mRNA molecule. In the
present manuscript, the discrepancies observed between the
treatments with antagonists and antisense oligonucleotides (i.t.)
may be justified initially by a higher affinity and specificity of the
antisense oligonucleotides in inhibiting spinal cannabinoid
receptor expression, mainly in DRG neurons, as discussed
earlier. Moreover, unlike antagonists that inhibit preformed
cannabinoid receptors, treatment with antisense oligonucleotides
shows a greater selectivity and efficacy in inhibiting protein
translation of these receptors, which could justify, for instance, a
greater effect of antisense treatment on reversing the analgesic
effect of WIN 55,212-2.
The data presented herein show, for the first time that the
brachial plexus avulsion model produced an increase in CB1 and
CB2 mRNA expression levels at different time-points after surgery.
Moreover, the mechanical allodynia produced by BPA was
accompanied by an increase in glial cell activation and expression
of p38 and JNK MAP kinases, associated with activation of the
transcription factors CREB and p65 NF-kB. We reported that
cannabinoid agonists display marked antinociceptive effects in the
BPA mouse model, and that such actions are dependent on their
ability to activate mainly CB2 receptors in the initial phase, and
both CB1 and CB2 receptors in the late phase after BPA surgery.
The cannabinoid agonist analgesic properties observed in the BPA
model are related to the inhibition of glial cells and MAP kinase
activation, associated with an enhancement of CREB and p65 NF-
kB activation. Altogether, our findings suggest that cannabinoid
agonists, acting via the activation of both CB1 and CB2 receptors,
could represent attractive and useful strategies to control long-
lasting neuropathic pain states, such as that observed after BPA.
Furthermore, we believe that our study contributes to compre-
hending the role played by cannabinoid receptors following
neuropathic injury.
Materials and Methods
Animals
Experiments were performed using female CD1 mice weighing
20 to 30 g (n=4–6 per group). Animals were housed under
conditions of optimum light, temperature and humidity (12 h
light/dark cycle, 2261uC, under 60–80% humidity), with food
and water provided ad libitum. The studies reported in this
manuscript followed the ‘‘Guide for the Care and Use of
Laboratory Animals’’ as adopted and promulgated by the U.S.
National Institutes of Health, and the ethical guidelines for the
investigation of experimental pain in conscious animals [36]. The
Ethics Committee of the Universidade Federal de Santa Catarina
approved all the experimental procedures (046/CEUA/PRPE/
2008). The number of animals and the intensity of noxious stimuli
used were the minimum necessary to demonstrate the consistent
effects of drug treatment.
Surgical procedures for BPA
BPA was performed according to the methodology previously
described and validated by Quinta ˜o et al. [37]. During surgery, the
animals were anesthetized by inhalation with 3% isoflurane plus
3% oxygen. The right brachial plexus was approached through a
longitudinal incision parallel to the clavicle, running from the
sternum to the axillary region (1 cm). The subclavian vessels were
located, and the lower trunk was dissected. The lower trunks were
extorted by traction using forceps. In the sham-operated group,
the brachial plexus was exposed and dissected without any lesion
to the nerve. The tissue layers were then brought together, and the
skin was closed with 4.0 silk suture strings (Ethicon, Edinburgh,
UK).
Hindpaw withdrawal response induced by von Frey hairs
To assess mechanical allodynia, mice were individually placed
in clear Plexiglas boxes (967611 cm) on elevated wire-mesh
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hindpaw. The animals were acclimatized for 30 min before
behavioral testing. The withdrawal response frequency was
measured after 10 applications (duration of 1 s each) of von Frey
hair 0.4 g (VFH; Stoelting, Chicago, IL). The 0.4 g VFH produces
a mean withdrawal frequency of about 20%, which is considered
to be an adequate value for the measurement of the mechanical
withdrawal threshold in naı ¨ve or sham-operated mice, providing
an adequate window to observe changes in mechanical sensation
in either inflammatory or neuropathic mouse models of nocicep-
tion. This choice was made considering that after BPA, both
sensory and motor fibers of the forepaws are partially disrupted
and the animals do not completely react to mechanical
stimulation. To determine the basal mechanical thresholds, all
the experimental groups were submitted to a pre-surgical
evaluation (basal assessment) and they were re-evaluated at time
0 (before drug treatment), on the 5
th and 30
th days after surgery
and at several time-points after agonist treatment (at 1, 2, 4, 6 and
8 h after treatment).
Effect of cannabinoid agonists on the allodynia induced
by BPA
The effects of cannabinoids on neuropathic pain following BPA was
initially evaluated by using the non-selective agonist of CB1 and CB2
receptors WIN 55,212-2 (R-[2,3-dihydro-5-methyl-3(4-morpholinyl-
methyl)pyrrolo[1,2,3,-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl metha-
none mesylate), dosed at different time intervals and routes of
administration. As a first experimental approach, operated mice were
treated with WIN 55,212-2 on the following schedule of administra-
tion: 10 and 30 mg/site, intraplantar (i.pl) in the right hindpaw; 3 and
5 mg/kg, intraperitoneally (i.p.); 1 and 5 mg/site, intrathecally (i.t.); or
1a n d5mg/site, intracerebroventricularly (i.c.v.). Treatment with the
agonists was performed at 5 or 30 days after surgery, and mechanical
allodynia was evaluated as previously described. These time points
were chosen on the basis of previous literature showing that these are
suitable intervals of time to evaluate the acute (5
th day) and long-lasting
(30
th day) changes evoked by BPA, without any interference of the
surgical procedures [37,38].
In another set of experiments, the operated mice received the
CB1 selective agonist ACEA ([N-(2-chloroethyl)5,8,11,14-eicosae-
traenamide]) (.1400-fold CB1 selectivity over CB2) (10 and
30 mg/site, i.pl; 1 and 10 mg/kg, i.p.; 10 and 30 mg/site, i.t.; or 10
and 30 mg/site, i.c.v.), or the CB2 selective agonist JWH-015 (2-
methyl-1-propyl-1H-indol-3-yl)-1-naphthalenylmethanone) (.23-
fold CB2 selectivity over CB1) (1 and 10 mg/site, i.pl; 1 and
10 mg/kg, i.p.; 1 and 10 mg/site, i.t.; or 1 and 10 mg/site, i.c.v.),
administered on the 5
th or the 30
th day after surgery. The doses of
agonists used in our study were selected on the basis of literature
data or pilot experiments [10,39–43].
Influence of CB1 and CB2 selective antagonists on the
analgesic effects elicited by a cannabinoid agonist
To confirm the effect of cannabinoid agonists in reducing the
mechanical allodynia induced by BPA, different groups of mice
were pre-treated with the selective CB1 AM 251 (3 mg/kg, i.p.) or
CB2 AM 630 (1 mg/kg, i.p.) receptor antagonists, dosed 30 min
prior to treatment with the non-selective cannabinoid agonist,
WIN 55, 212-2 (3 mg/kg, i.p.), on the 5
th or 30
th day after surgery.
Mechanical allodynia was measured with 0.4 g von Frey filament
(VFH), as described above, at different time-points. The doses of
antagonists used in our study were selected on the basis of
literature data [3].
Influence of CB1 and CB2 knockdown on the analgesic
effects elicited by a cannabinoid agonist
To further confirm the effects of cannabinoids in neuropathic
pain following BPA, different groups of mice received on the 2
nd or
the 27
th day after BPA surgery, over a period of three days at 12 h
intervals, i.t. injections of antisense oligodeoxynucleotides (AS-
ODN) directed against the specific coding region of the CB1 (CB1
AS-ODN, sequence 59-GCCGTCTAAGATCGACTT-39)o r
CB2 receptor (CB2 AS-ODN, sequence 59-CTGCTGAGCGC-
CCTGGAGAAC-39). The control groups received i.t. injections of
mismatch ODN control (MM AS-ODN, sequence 59-GCC-
TGCTAGAATCGCATT-39). AS-ODN (12.5 mg) was injected
by the i.t. route in a volume of 5 ml (2.5 mg/ml). At the end of the
third injection day, mice also received WIN 55,212-2 (3 mg/kg,
i.p.) or vehicle (10 ml/kg, i.p.), 30 min after the last i.t. injection.
Mechanical allodynia was measured with 0.4 g von Frey filament
(VFH), as described above, at different time-points. To prove the
efficacy of treatment with AS-ODN directed to CB1 and CB2
receptors, the cervical-thoracic portion (C4-T2) of the spinal cord
of AS-ODN-treated mice was analysed immunohistochemically as
described below.
Effect of cannabinoid agonists on the activation of glial
cells, MAP kinases and transcription factors pathways
activated after BPA
To investigate the involvement of cannabinoids on the
activation of glial cells, MAP kinases and transcription factors
involved in neuropathic pain, we performed two treatment
protocols. First, mice received a single i.p. injection of WIN
55,212-2 (3 mg/kg) on the 5
th and 30
th days after surgery. In the
second protocol, mice received five treatments of WIN 55,212-2
(3 mg/kg, i.p.), starting on the 3
th or 27
th day after surgery (12/
12 h), and 2 h after the last treatment (on the 5
th or 30
th day after
surgery), mice were anesthetized with 7% chloral hydrate (10 ml/
kg, i.p.) and perfused with PBS solution containing 4%
paraformaldehyde (PFA). The cervical-thoracic portion of the
spinal cord (C4 to T2) was collected and fixed in 4%
paraformaldehyde in 0.2 M sodium phosphate, pH 7.4, for
subsequent immunohistochemical analysis. The results obtained
for treated operated mice were compared with those obtained for
operated mice that had received vehicle only.
Immunohistochemical studies
On the 5
th or the 30
th day following BPA, mice were
anesthetized with 7% chloral hydrate (10 ml/kg, i.p.) and perfused
with fresh 4% paraformaldehyde in 0.2 M sodium phosphate,
pH 7.4. Immunohistochemical analysis were performed on
paraplastH-embedded tissue sections (5 mm) of DRGs (C4-T2
spinal cord segment), cervical-thoracic spinal cord (C4-T2 spinal
cord segment) and somatosensory cortex (cingulate cortex) using
polyclonal rabbit anti-CB1 (1:500), polyclonal rabbit anti-CB2
(1:150), polyclonal goat anti-Iba-1 (ionized calcium binding
adaptor molecule 1) (1:200), monoclonal mouse anti-GFAP (glial
fibrillary acidic protein) (1:600), polyclonal rabbit anti-phospho-
CREB (1:200), polyclonal rabbit anti-phospho-p65 (NF-kB)
(1:100), monoclonal mouse anti-phospho-JNK (1:200) and poly-
clonal rabbit anti-phospho-p38 (1:60) antibodies. After quenching
of endogenous peroxidase with 1.5% hydrogen peroxide in
methanol (v/v) for 20 min, high-temperature antigen retrieval
was performed by immersion of the slides in a water bath at 95 to
98uC in 10 mmol/L trisodium citrate buffer, pH 6.0, for 45 min.
Subsequently, the sections were incubated overnight at 4uC with
the primary antibodies. After incubation with the appropriate
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ized with 0.05% 3,39-diaminobenzidine tetrahydrochloride (DAB:
Dako Cytomation, Glostrup, Denmark)+0.03% H2O2 in PBS (for
the exact amount of time of 10 seconds;, the reaction was stopped
by thorough washing in water and sections were counterstained
with Harris’ hematoxylin. Control and experimental tissues were
placed on the same slide and processed under the same conditions.
Besides staining untreated animals as negative controls, sections
were incubated with isotype-matched primary antibodies of
irrelevant specificity, or the primary antibody was omitted.
Despite antigen retrieval, these controls resulted in little or no
staining, principally due to the fact that peroxide pre-treatment
(inactivation of endogenous peroxidase) appears to destroy the
epitopes to which secondary antibody otherwise binds. Images
were acquired using a Sight DS-5M-L1 digital camera connected
to an Eclipse 50i light microscope (both from Nikon, Melville, NY,
USA). Settings for image acquisition were identical for control and
experimental tissues. Four microscopic fields (4006) per section of
the DRG and of the dorsal horn of the spinal cord regions
associated primarily with the termination of nociceptive primary
afferents were captured and a threshold optical density that best
discriminated staining from the background was obtained using
ImageJ 1.36b imaging software (NIH, Bethesda, MD, USA). The
nucleus proprius (lamina IV and V) and the ventral horn of the
spinal cord were not evaluated. For all antibodies, analysis of the
dorsal root of the spinal cord and the DRG, was performed using
total pixel intensity, and data were expressed as arbitrary units.
The cervical-thoracic portion of the spinal cord was used for
expression studies, considering that it is the area responsible for the
innervation of the brachial plexus.
Determination of cannabinoid receptor expression by
real-time quantitative-PCR
The expression of CB1R and CB2R mRNA was measured using
quantitative RT-PCR assays. Separate groups of operated and
sham-operated mice were killed on the 5
th or the 30
th day
following BPA, and the ipsilateral dorsal root ganglion (DRG) and
the spinal cord from the cervical portion (C4-T2 spinal cord
segment) were isolated, dissected and frozen in liquid nitrogen and
stored at 280uC. Total RNA from tissues was collected and
extracted using the TRizol protocol and its concentration was
determined using a NanoDrop 1100 (NanoDrop Technologies,
Wilmington, DE, USA). The reverse transcription assay was
carried out as described in the M-MLV Reverse Transcriptase
protocol according to the manufacturer’s instructions. cDNA
(300 ng) was amplified in triplicate using TaqManH Universal
PCR Master Mix Kit with specific TaqMan Gene Expression
target genes, with 39 quencher MGB and FAM-labeled probes
directed against the cDNA for the CB1 (Mm01212171_s1) and
CB2 (Mm00438286_m1) receptors, as well as GAPDH
(Mm03302249_g1), which was used as an endogenous control
for normalization. The PCR reactions were performed in a 96-
well Optical Reaction Plate (Applied Biosystems, Foster City, CA,
USA). The thermocycler parameters were as follows: 50uC for
2 min, 95uC for 10 min, 50 cycles of 95uC for 15 sec, and 60uC
for 1 min. Fluorescence was measured for each amplification cycle
and the data were analyzed using the 2
2DDCT method for relative
quantification of expression. Expression of the target genes was
calibrated against conditions found in control animals, i.e., those
which received the vehicle.
General drug administration procedures
The i.t. injections were performed in conscious animals to
avoid possible anesthetic interference, according to the method
described by Hylden and Wilcox [44], with some modifications. A
needle connected to a microsyringe by polyethylene tubing was
introduced through the skin, and a volume of 5 ml of vehicle
(control) or one of the cannabinoid agonists was injected between
the L5 and L6 vertebral spaces. For i.c.v. injections, the animals
were slightly anesthetized by inhalation with 3% isoflurane plus
3% oxygen, and a free-hand injection of a 2 ml volume of agonists
or vehicle was injected directly into the left ventricle of the brain,
as described previously by Laursen and Belknap [45].
Drugs and reagents
R-[2,3-dihydro-5-methyl-3(4-morpholinylmethyl)pyrrolo[1,2,3,
-de]-1,4-benzoxazin-6-yl]-1-naphthalenyl methanone mesylate
(WIN 55,212-2), (2-methyl-1-propyl-1H-indol-3-yl)-1-naphthale-
nylmethanone (JWH-015), [N-(2-chloroethyl)5,8,11,14-eicosae-
traenamide] (ACEA), and paraplastH were purchased from
Sigma Chemical Company (St. Louis, MO, USA). The 6-iodo-
2-methyl-1-[2-(4-morpholinyl)ethyl]-1H-indol-3-y l](4-methoxyphenyl)
methanone (AM 630) and N-(piperidin-1-yl)-5-(4-iodophenyl)-1-(2,4-
dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (AM 251) were
purchased from Tocris Bioscience (Ellisville, MO, USA). Isoflurane
was obtained from Crista ´lia (Sa ˜o Paulo, SP, Brazil). Chloral hydrate
was purchased from Vetec (Rio de Janeiro, RJ, Brazil). The antisense
oligodeoxynucleotides specific for CB1 (CB1 AS-ODN), CB2 (CB2 AS-
ODN) or the mismatch (MM AS-ODN) were purchased from
Prodimol Biotecnologia (Belo Horizonte, MG, Brazil). TRizol was
purchased from Invitrogen (Carlsbad, CA, USA), Oligo dT, M-MLV
reverse transcriptase, dNTP, DTT and Tris-HCl and RNAsin from
Promega (Madison, WI, USA) PCR master mix kit and FAM-labeled
probes for CB1,C B 2 and GAPDH from Applied Biosystems (Foster
City, CA, USA), phosphate buffered saline (PBS), trisodium citrate,
hydrogen peroxide, Harris’ hematoxylin, MgCl2, KCl, paraformalde-
hyde, ethanol, xylene, methanol, acetone, dimethylsulfoxide and
Tween 80 from Merck & Co., Inc. (Whitehouse Station, NJ, USA).
Polyclonal rabbit anti-CB1 and polyclonal rabbit anti-CB2 antibodies
were purchased from Cayman Chemicals (Ann Arbor, MI, USA),
monoclonal mouse anti (phospho)-JNK from Santa-Cruz Biotechnol-
ogyInc.(S antaCr uz ,CA,US A).Polyc lonalrabbit anti-phosphorylated
p38 (Thr180 and Tyr182), monoclonal mouse anti-GFAP, polyclonal
rabbit anti-p-CREB (Ser133) and polyclonal rabbit anti-p-p65 NF-kB
(Ser276) were obtained from Cell Signaling Technology (Beverly, MA,
USA). Polyclonal goat anti-Iba-1 was purchased from Abcam
(Cambridge, MA, USA). Streptavidin-horseradish peroxidase and
3,39-diaminobenzidine (DAB) were purchased from Dako (Glostrup,
Denmark).WIN 55,212-2 wasdissolved in 2% DMSO and 2% Tween
80. Stock solutions were prepared with 100% ethanol for JWH-015
and 100% DMSO for ACEA. The final concentration of ethanol or
DMSO never exceeded 5%, which had no effect per se in our protocols.
The control groups received the respective vehicle used to dissolve the
drugs.
Statistical analysis
The results are presented as the mean 6 SEM of four to six
animals for each experimental group. For the behavioral
nociception assays, the percentages of inhibition are reported as
the difference (in percentage) between the areas under the time-
response curve of the test group in relation to the corresponding
control group. Statistical comparison of data was performed by
two-way ANOVA for repeated measures followed by Bonferroni’s
post-hoc test (treatment and time variable) or one-way ANOVA
followed by Bonferroni’s post-hoc test, depending on the
experimental protocol. P values less than 0.05 (p,0.05) were
considered significant. Statistical analyses were performed using
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Diego, CA, USA).
Supporting Information
Figure S1 The CB1 receptor (CB1) and CB2 receptor
(CB2) immunoreactivity in CNS structures of mice
submitted to brachial plexus avulsion (BPA). CB1 and
CB2 receptor expression were evaluated in the DRG, the dorsal
horn of the spinal cord and the cingulate cortex in N (naı ¨ve mice),
Sh 5 d (sham-operated group 5 days after BPA), Op 5 d (operated
group 5 days after BPA), Sh 30 d (sham-operated group 30 days
after BPA) and Op 30 d (operated group 30 days after BPA). The
scale bar corresponds to 50 mm and applies throughout.
(TIF)
Figure S2 Immunoreactivity against glial cells, MAP
kinases and transcription factors in the dorsal horn of
the spinal cord of mice submitted to brachial plexus
avulsion (BPA). Immunostaining of activated microglia (Iba-1),
astrocytes (GFAP), phospho-p38 (p-p38) and phospho-JNK (p-
JNK) MAP kinases, phospho-CREB (p-CREB) and phospho-p65
NF-kB (p-p65) transcription factors in N (naı ¨ve mice), Sh 5 d
(sham-operated group 5 days after BPA), Op 5 d (operated group
5 days after BPA), Sh 30 d (sham-operated group 30 days after
BPA) and Op 30 d (operated group 30 days after BPA). The scale
bar corresponds to 50 mm and applies throughout.
(TIF)
Figure S3 Local administration of cannabinoid agonists
inhibits mechanical allodynia induced by brachial
plexus avulsion (BPA) in mice. Response frequency of the
right hindpaw assessed at several time-points in operated (BPA)
mice treated with the non-selective CB1 and CB2 agonist, WIN
55,212-2 (10–30 mg/paw, i.pl.), the selective CB1 agonist, ACEA
(10–30 mg/paw, i.pl.), the selective CB2 agonist, JWH-015 (1–
10 mg/paw, i.pl.) or vehicle (20 ml/paw, i.pl.), administered on the
5
th (A, B and C) and 30
th (D, E and F) day after surgery. Data are
expressed as mean 6 SEM (n=4–6/group). *p,0.05, significantly
different from the operated group treated with vehicle (two-way
ANOVA with Bonferroni’s post hoc test). B, Baseline withdrawal
threshold before surgery. 0, baseline withdrawal threshold after
surgery on the day of the experiment (5
th and 30
th days).
(TIF)
Figure S4 Effect of treatment with selective antisense
oligodeoxinucleotide (AS-ODN) on CB1 and CB2 receptor
expression in the spinal cord of mice. Immunostaining of
activated of CB1 and CB2 receptors in operated (Op) mice
received an i.t. injection twice daily of mismatch (MM) AS-ODN
(12.5 mg/site), CB1 AS-ODN (12.5 mg/site) or CB2 AS-ODN
(12.5 mg/site) on the 5
th and 30
th day after brachial plexus avulsion
(BPA). The scale bar corresponds to 50 mm and applies
throughout.
(TIF)
Figure S5 Effect of cannabinoid agonist on the expres-
sion of glial cells, MAP kinases and transcription factors
in the dorsal horn of the spinal cord after brachial
plexus avulsion (BPA) in mice. Immunostaining of activated
microglia (Iba-1), astrocytes (GFAP), phospho-p38 (p-p38) and
phospho-JNK (p-JNK) MAP kinases, phospho-CREB (p-CREB)
and phospho-p65 NF-kB (p-p65) transcription factors in operated
mice treated with vehicle (10 ml/kg, i.p.), acute (once) or long-
term (five times) treatment with WIN 55,212-2 (3 mg/kg, i.p.) on
the 5
th and 30
th days after BPA. The scale bar corresponds to
50 mm and applies throughout. JNK: c-Jun N-terminal kinase;
CREB: cAMP response element-binding protein; p65 NF-kB:
nuclear phospho-p65 nuclear factor-kB (NF-kB).
(TIF)
Table S1 Behavioral effects of cannabinoids agonists in
the mouse tetrad assay.
(DOC)
Supplementary Methods Tetrad behavioral assessment.
(DOC)
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